Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.

Émilie Gobeil Jérôme Bourgault Patricia L Mitchell Ursula Houessou Éloi Gagnon Arnaud Girard Audrey Paulin Hasanga D ManikpurageValérie CôtéChristian Couture Simon Marceau Yohan Bosse Sébastien Thériault Patrick Mathieu Marie-Claude Vohl Andre Tchernof Benoit J Arsenault

Published in: European heart journal (2024)

PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk.

Keyphrases

poor prognosis
binding protein
gene expression
amino acid
long non coding rna